Notícias

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence.

UBS analyst David Dai raised the firm’s price target on IOVA to $7 from $4 on Thursday while maintaining a Neutral rating.

Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

IOVA’s rally coincides with positive sentiment across melanoma-focused biotech stocks after Merck and Moderna announced successful late-stage data for their personalized mRNA cancer vaccine on Wednesday.

Investors responded to clinical progress, improving commercial performance and new growth opportunities.

Why Iovance Biotherapeutics stock is back in focus after Q2 earnings Iovance Biotherapeutics (IOVA) is back on investor radars after its second quarter 2026 earnings. The company reported higher revenue and a reduced net loss, and it reaffirmed full year revenue guidance. The quarter was driven by Amtagvi and Proleukin sales, and by progress across Iovance Biotherapeutics pipeline programs, including new regulatory approvals and Fast Track designations for lifileucel in certain soft tissue...

Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.

The healthcare stock is now up more than 130% this year.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

Moby summary of Iovance Biotherapeutics, Inc.'s Q2 2026 earnings call

The rally showed that investors are paying more attention to fast-growing healthcare and digital media companies.

Iovance Biotherapeutics Inc (IOVA) reports record Q2 2026 revenue of $99.3 million, driven by strong Amtagvi demand and all-time high gross margins of 56%.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) rocketed to a fresh 52-week high on Thursday, clocking as much as 47 percent gains, after management reported a 66 percent jump in revenues that signaled the strengthening demand for its treatment for advanced melanoma. In intra-day trading, the stock surged to its highest price of $6.39 before trimming gains to […]

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

The biotech company reported record second-quarter revenue fueled by strong sales of its cancer therapy Amtagvi.

Record quarterly revenue, improving margins and continued commercial momentum are prompting Iovance to reassess its full-year guidance while advancing multiple late-stage clinical programmes. Key Investor TakeawaysIovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue of approximately $99.

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics stock has rebounded strongly in the short term, yet its longer track record and current valuation checks paint a more mixed picture that investors need to weigh carefully. After a steep multi year share price decline, the broader valuation framework now points to Iovance as screening cheap on several measures. Iovance Biotherapeutics shares have declined 82.7% over the past 5 years, which highlights how much long term holders have been hurt and why any apparent value...

Iovance Biotherapeutics recently announced it will report its second quarter 2026 results and corporate updates on August 6, 2026, drawing attention as Wall Street anticipates a quarterly loss alongside higher year-over-year revenue. Analysts’ earnings revisions and a negative Earnings ESP highlight uncertainty around the upcoming report, even as interest in Iovance’s TIL-based Amtagvi® therapy and broader pipeline remains elevated. Next, we’ll examine how this upcoming earnings release and...

Iovance Biotherapeutics (IOVA) is drawing attention ahead of its second quarter 2026 earnings report and corporate update scheduled for August 6, 2026, which will be presented alongside its first FDA-approved T cell therapy for solid tumors. See our latest analysis for Iovance Biotherapeutics. The latest pullback in Iovance Biotherapeutics, with a 1-day share price return down 13.22% and 7-day share price return down 18.44% to US$4.07, sits against a stronger backdrop that includes a 30-day...

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Apogee Therapeutics Inc. (APGE) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks to Invest In According to Billionaires. Recently, on June 30, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) updated its corporate presentation, highlighting its position as a global leader in tumor-infiltrating lymphocyte cell therapy. ​The update noted that the company has now treated more than 1,500 patients through […]

The biotech is clearly innovative, but sometimes that's not enough.

Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Resilient Stocks Beating Market Slump. Iovance Biotherapeutics saw its share prices increase by 9.36 percent to close at $4.44 apiece, as investors positioned portfolios ahead of the end of the second quarter, supported by a recent regulatory approval that opened the door for its expansion into […]